Company intelligence / Profile preview

RLS Global

Ownership: Private
Employees: ~9
Development stage: Commercial

Overview

RLS Global is a Swedish medical technology company focused on developing and commercializing minimally invasive biochemical solutions for wound care and oral health. Its lead product ChloraSolv is used to treat chronic diabetic foot and leg ulcers by facilitating gentle debridement. CariSolv is a gel-based system for minimally invasive removal of dental caries. The company also markets PeriSolv for periodontitis treatment and Kindersolv as a pediatric version of its dental gel. Products are sold primarily through distributors with commercial presence mainly in Sweden but with global ambitions.

Therapeutic areas: OtherEndocrinologyDermatology
Modalities: BiologicSmall molecule
Industry: Biotech

Drug pipeline

2 assets

ChloraSolv

Unknown

1 more asset in the full pipeline.

Partnerships

Not explicitly listed; distribution partnerships globally implied.

Beyond the preview

Go deeper on RLS Global.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RLS Global.